Management uses the non-GAAP financial measures to evaluate Par financial performance against internal budgets and targets. Subjects who cumpara mai ieftin ondansetron do not tolerate venipuncture will not be allowed to participate. SciClone has exclusive marketing rights to DC Bead in China, where the product is under regulatory review. Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis. The Company leadership in thin film drug delivery is supported by strong intellectual property, portfolio of commercialized over-the-counter OTC drug products, and development pipeline of prescription formulations based on PharmFilm technology. Please also refer to other risks and uncertainties described in SciClone filings with the SEC. In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating Par underlying business performance.